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Abstract
Missense mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are linked to autosomal dominant forms of Parkinson’s
disease (PD). In order to get insights into the physiological role of Lrrk2, we examined the distribution of Lrrk2 mRNA and
different splice variants in the developing murine embryo and the adult brain of Mus musculus. To analyse if the Lrrk2-
paralog, Lrrk1, may have redundant functions in PD-development, we also compared Lrrk1 and Lrrk2 expression in the same
tissues. Using radioactive in situ hybridization, we found ubiquitous expression of both genes at low level from embryonic
stage E9.5 onward, which progressively increased up until birth. The developing central nervous system (CNS) displayed no
prominent Lrrk2 mRNA signals at these time-points. However, in the entire postnatal brain Lrrk2 became detectable,
showing strongest level in the striatum and the cortex of adult mice; Lrrk1 was only detectable in the mitral cell layer of the
olfactory bulb. Thus, due to the non-overlapping expression patterns, a redundant function of Lrrk2 and Lrrk1 in the
pathogenesis of PD seems to be unlikely. Quantification of Lrrk2 mRNA and protein level in several brain regions by real-
time PCR and Western blot verified the striatum and cortex as hotspots of postnatal Lrrk2 expression. Strong expression of
Lrrk2 is mainly found in neurons, specifically in the dopamine receptor 1 (DRD1a) and 2 (DRD2)-positive subpopulations of
the striatal medium spiny neurons. Finally, we identified 2 new splice-variants of Lrrk2 in RNA-samples from various adult
brain regions and organs: a variant with a skipped exon 5 and a truncated variant terminating in an alternative exon 42a. In
order to identify the origin of these two splice variants, we also analysed primary neural cultures independently and found
cell-specific expression patterns for these variants in microglia and astrocytes.
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Introduction
Parkinson’s Disease (PD), as the second most common
neurodegenerative disorder, affects 1–2% of the population over
the age of 65 (rising to 4–5% of the population from the age of 85)
[1–3]. Even though the majority of PD cases are sporadic (.90%),
several familial forms of the disease – which could be linked to a
single genetic factor – were identified over the last fifteen years
[4,5]. Missense mutations in the LRRK2 gene (dardarin), which are
linked to changes in the coding region of the PARK8 locus [6–8],
represent the most common cause of familial (up to 10% overall;
up to 40% in certain ethnic populations) and sporadic (1–2%) late-
onset forms of PD [7–14]. In contrast to hereditary loss-of-function
PD-forms, LRRK2 missense mutations do not interfere with the
expression of this large multi-domain protein. Nevertheless, the
activity of distinct protein domains is altered. The neuropathology
of LRRK2-associated PD is heterogeneous and features the
classical nigral degeneration with or without the presence of Lewy
bodies and ubiquitin-positive or tau-positive inclusions [8,15–18].
The Lrrk2 gene is comprised of 51 exons coding for a large 2527
amino acid multi-domain protein [7]. It shares high homology
with its slightly shorter paralog Lrrk1– another member of the
ROCO protein kinase superfamily [19,20]. Both proteins contain
two domains, Roc (Ras in complex proteins, belonging to the Ras/
GTPase family) and COR (C-terminal of Roc) characteristic of
ROCO proteins [19], as well as the catalytic kinase domain with
close sequence homology to MAPKKKs of the MLK (mixed
lineage kinases)-type. In addition, several other domains are found
in LRRK1 and/or LRRK2: LRRK2-specific repeats (only in
LRRK2), ankyrin repeats (in both) and leucine-rich repeats (LRR,
in both) plus a WD40 domain towards the C-terminus (only in
LRRK2) [8,20,21]. Although mutations are spread over the whole
LRRK2 gene, most of the pathogenic mutations are found either in
the kinase (G2019S, I2020T), COR (Y1699C) or Roc-GTPase
domain (R1441C/G/H). In vitro data suggests that GTP binding
promotes LRRK2 kinase activity and enhances neurotoxicity,
indicating a gain-of-function mechanism in the etiology of PD
[22–26]. A similar intramolecular, regulatory mechanism has also
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been reported for LRRK1 [27], but interestingly, no mutation
clearly segregating with PD could be identified in this gene so far
[28,29]. Nevertheless, due to the highly conserved protein
structures of both proteins it has been proposed that there might
be a redundancy in their, up to now still unknown, physiological
functions [30,31]. Thus, detailed analysis of the organ and brain
distribution of Lrrk1 and Lrrk2 could provide valuable hints
towards their function. Therefore, in this study a series of detailed
and comparative expression analyses for mammalian Lrrk1 and
Lrrk2 was performed in mouse. Different analytical methods using
samples from early stages of murine embryonic development until
adulthood were used for this including: (i) Localization and
expression level of Lrrk1 and Lrrk2 were analysed by radioactive in
situ hybridization (ISH) in sections of whole embryos, postnatal,
adult and aged brains. (ii) Expression level of Lrrk2 mRNA were
quantified by real-time PCR and protein level by Western blot in
several brain regions. (iii) Lrrk2 co-expression in different neuronal
populations of the striatum and cortex were analysed by
immunohistological stainings. (iv) In addition, two splice-variants
of Lrrk2 were identified in RNA samples from different adult brain
regions and organs. Taken together, this is the first time that Lrrk1
and Lrrk2 expression (localization, expression level, cellular
distribution and splicing) were analysed using a comparative
approach with a number of independent highly sensitive analytical
methods (qualitative and quantitative) in parallel. This combina-
tion of high-resolution ISH images; region-specific quantification
of mRNA and protein level by real-time PCR and Western blot
respectively; immunohistochemical analysis of the distribution in
neuronal populations and the identification of cell-type specific
splice variants is the basis for new insights into potential Lrrk2
function.
Materials and Methods
Animals Housing and Tissue Preparation
All animal work was carried out in accordance with the
European Communities’ Council Directive 2010/63/EU. All
efforts were made to minimize animal suffering during the work.
All protocols involving animal handling were approved by the
committee for the Care and Use of Laboratory animals of the
Government of Upper Bavaria, Germany. C57BL/6J mice
(obtained from Charles River Germany) were group housed in
individually ventilated type IIL cages (four mice per cage) and
maintained on a 12 h/12 h light/dark cycle with food and water
available ad libitum.
Mice were sacrificed and immediately thereafter intracardially
perfused with 200 ml of ice-cold paraformaldehyde (PFA, 4%,
pH 7.5). For post-fixation, the brains were incubated in PFA for
1–2 hours at RT. For embryo preparation, mothers were
sacrificed via cervical dislocation. Embryos were dissected and
immediately decapitated. Brains were dissected and immersion
fixed in PFA overnight at 4uC. For embedding, brains were
dehydrated through an ascending ethanol series (30%, 50%, 75%,
85%, 95% and 26100%; 90 min per step), clarified for 2660 min
in 100% RotiHistolH (Carl Roth GmbH, #6640) at RT,
equilibrated for 60 min in a 1:1 mixture of RotiHistolH/paraffin
at 65uC, transferred for 60 min into 100% paraffin at 65uC and
incubated for 8 h in 100% paraffin at 65uC. At the end, samples
were cooled down to room temperature in 100% paraffin
(embedding) and stored at 4uC until cutting. Paraffin embedded
brain tissue were cut on a Cryostat (MICROM, Heidelberg,
Germany) in three different planes (coronal, sagittal and horizon-
tal), put into a water bath (37–42uC) for flattening and mounted on
SuperFrostH Plus slides (Menzel-Gla¨ser, #J1800AMNZ), dried
overnight on a heating plate and/or in an incubator at 37uC and
stored at 4uC until use.
Western Blot Analysis
LRRK2 expression analysis on protein level was performed
using total protein samples from different brain as previously
described by Gloeckner et al. [32] After blotting, bands were
detected by monoclonal rat anti-Lrrk2 antibodies (1E11, produced
by E. Kremmer, [32–36]) and HRP-coupled anti-rat secondary
antibodies (Jackson Immunoresearch, #112-035-044). For mea-
suring protein loading, mouse anti-b-actin antibodies (GeneTex,
#GTX26276) and HRP-coupled anti-mouse secondary antibodies
(Jackson Immunoresearch, #115-035-003) were used. Bands were
visualized using the ECL detection kit (GE Healthcare).
In situ Hybridization
ISH has been performed on paraffin sections using either
[35S]-UTP-radiolabeled (Perkin Elmer) or digoxigenin (DIG)
labeled riboprobes according to manufacturer’s protocol
(Roche). The applied protocol is based on the published
protocol of Dagerlind and colleagues [37]. In brief, 8 mm thick
paraffin sections were rehydrated, partially digested with
proteinase K, acetylated, dehydrated again and prehybridized
in 100 ml hybridisation mix (containing 50% deionized form-
amide, 46 SSC, 0.56 Denhardt’s solution, 1% N-lauroylsarco-
sine, 20 mM Na-phosphate buffer and 10% Dextran sulphate)
per slide for 1 h at 58uC. Following that, the slides were
incubated with either [35S]-UTP-radiolabeled (1?106 counts per
million/slide) or DIG-labeled riboprobes (15–30 ng/slides) in
100 ml hybridisation mix per slide overnight at 58uC. Washing
was performed in decreasing concentrations (46 to 0.16) of
saline sodium citrate (SSC) at RT, except the final washing step
in 0.16 SSC for 2630 minutes at 65uC). For the radioactive
ISH, the hybridized slides were dehydrated and dipped in
autoradiographic emulsion (Kodak NTB2), developed after 4–6
weeks and counterstained with cresyl violet according to
standard protocols. For detecting DIG-labeled riboprobes, an
anti-DIG antibody coupled to the alkaline phosphatase (AP)
enzyme has been used; subsequent either nitro blue tetrazolium
and 5-bromo-4-chloro-3-indolyl phosphate (Boehringer Man-
nheim, Germany) or a tyramide–cyanine 3 TSA kit (Perkin
Elmer Life Sciences, Boston, USA) have been used as
chromophore. Riboprobes were obtained from cDNA fragments
cloned into the pCRTMII-TOPOH vector (Life Technologies,
Carlsbad, USA) by in vitro transcription by RNA polymerase T3,
T7 or SP6, either utilizing [35S]-UTP (Perkin Elmer Life
Sciences, Boston, USA) or DIG-labeling mix according to
manufacturer’s protocol (Roche, Mannheim, Germany). To
obtain specific ISH-probes for Lrrk1 and Lrrk2, several
overlapping and non-overlapping cDNA fragments have been
amplified from murine total mRNA by RT-PCRs. Sequences of
used primers can be found in (Figure S9).
Immunhistochemistry on Paraffin Sections
IHC on paraffin sections was performed in coplin jars except for
blocking reactions, antibody incubations, incubation with ABC-
reagent and DAB-stainings. Glass slides were dewaxed for 45 min
in xylol, rehydrated in a series of descending alcohol (100%, 96%
and 70%) and rinsed with water. To destroy endogenous
peroxidases, slides were incubated for 5 min in 0.1% H2O2 (in
PBS) before blocking for 1 h in 10% FCS (with 0.05% Triton-X in
PBS). Primary antibodies against DARPP-32 (Abcam, ab40801),
dopamine D1 receptor (Calbiochem, #324390), dopamine D2
receptor (Chemicon, AB5084P), NeuN (Chemicon, MAB377)
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were diluted in 10% FCS (with 0.05% Triton-X in PBS) and
incubated overnight at 4uC in a humid chamber. Appropriate
secondary antibodies were then applied on the next day diluted in
10% FCS (with 0.05% Triton-X in PBS) for 1 h at RT in a humid
chamber. Next, the DAB working solution (Sigma) was freshly
prepared (1 ml DAB stock solution, 15 ml 30% H2O2 and 19 ml
0.1 M Tris-HCl, pH 7.4) and applied to the sections for 30 min in
a humid chamber. Finally, sections were dehydrated in a series of
descending alcohol (70%, 96% and 100%) and xylol and
embedded in Roti-HistoKit II (Carl Roth GmbH).
Reverse Transcriptase and Quantitative Real-time PCR
RT-PCR was performed on Trizol (Invitrogen, #15596-026) or
RNeasy Mini Kit (Quiagen) extracted RNA samples from
C57CL/6J mice. Reverse transcription was performed using
random hexamers and SuperScriptH-II (Invitrogen, #12371-019)
or SuperScriptH-VILO (Invitrogen, #11904-018) according to the
manufacturer’s instructions.
Quantitative Lrrk2 expression analysis was performed using
total RNA from different brain regions and the ABI PRISM 7900
Sequence Detection System (Applied Biosystems) and TaqManH
reaction mixes for endogenous Lrrk2 (Mm00481934_m1, Applied
Biosystems) and b-actin (NM_007393.1, Applied Biosystems). All
samples were measured in triplicates using the following PCR
program: an initial step of 95uC for 10 min and then 40 cycles of
95uC for 15 s and 60uC for 1 min. For quantification of Lrrk2
transcripts, three different qPCR reactions were performed from
each cDNA sample (endogenous LRRK2, alternative LRRK2 and
b-actin control). A 20 ml reaction contained 10 ml of TaqManH
Universal PCR Master Mix (Applied Biosystems), 2 ml cDNA
template, 300 nmol/L of each primer and 200 nmol/L of the
specific probe. Sequences of used primers and probes can be found
in (Figure S9). For the b-actin control reaction an ACTB
TaqManH Gene Expression Assay Mix Mouse (Applied Biosys-
tems) was used. No template controls (NTC) were included in each
assay and amplification and detection were performed under
standard conditions as recommend by Applied Biosystems. The
fluorescent signal intensities were recorded and analysed during
PCR amplification using the Sequence Detection Software (SDS)
software (Applied Biosystems). To determine the LRRK2 ratios,
all values were initially normalized to the b-actin expression.
Following, the ratio of variant versus endogenous Lrrk2 was
determined (22[DDCTvariant2DDCTnormal]).
Preparation of Primary Neurons, Microglia and Astrocytes
Primary cortical neuronal cultures of C57BL/6J brains were
generated as previously described [38]. For preparation of
primary astrocyte and microglia cultures, newborn pups (1–
3 days old) were decapitated, brains were dissected free of the
meninges, and the cerebral cortices were isolated. Then, cortices
were mechanically dissociated and cells were resuspended in
astrocyte [DMEM (Invitrogen) supplemented with 10% FCS,
1% Pen/Strep, 10 ng/ml human EGF (Invitrogen) and murine
bFGF (Peprotech)] or microglia medium [DMEM/F12 (Invitro-
gen) supplemented with 10% FCS and 1% Pen/Strep],
respectively. Culture was performed in 6-well dishes at 5%
CO2 and medium was changed every 3–4 days. To deplete as
many microglia as possible, plates were shaken rapidly (15–30 s)
prior to each medium change (step done only for astrocyte
cultures). After confluency was reached, cultures were trypsi-
nated using a 1:3 dilution of 0.25% trypsin and serum-free
medium until the astrocyte containing cell layer slowly detached
(while the microglia stayed attached to the plate) [39]. To
harvest astrocytes, the floating cell-layer were transferred to a
new plate and dissociated by gentle pippeting for further
subculture. To harvest microglia, just new medium was added
to the old plates after astrocyte-removal and cells were used
after 3–6 days. The astrocyte-subculture procedure was repeated
3 times until cultures were taken for experiments and mitogens
were removed from the medium 4 days before RNA was
isolated.
Results
Comparative Expression Analysis of Lrrk1 and Lrrk2
during Murine Embryonic Development
The pattern of expression reflects the physiological role of a
protein. Thus, a comparative expression analysis of Lrrk2 and Lrrk1
was performed in C57BL/6J mice by radioactive ISH. This was
also to evaluate the possibility of redundant functions between
these two highly conserved paralogs. The main emphasis of this
expression analysis was put on the brain of adult mice; embryonic
development was also taken into account.
Lrrk2 mRNA was first analysed using semi-quantitative RT-
PCR in undifferentiated embryonic stem (ES) cells and in early
stages of embryonic development (E8.5 to E12.5 embryos) (Figure
S1A). In virtually all developmental stages and organs (from ES
cells until adulthood), expression of Lrrk2mRNA could be detected
(Figure S1A and data not shown). The earliest embryonic stage,
which was analysed by ISH, was E7.5 (Figure S1B). At this
developmental stage only the surrounding maternal tissue (i.e. the
parietal yolk sac) exhibited strong Lrrk2 expression, whereas signals
in the ectodermal, mesodermal and endodermal embryonic tissues
were too weak to be detected even by radioactive ISH (Figure
S1B). At embryonic stages E9.0 to E11.5, weak expression of Lrrk1
and Lrrk2 was observed widespread over the entire embryo beside
the neuroepithelium of the developing CNS. At stage E10, Lrrk1
showed distinct areas of stronger expression in the cephalic
mesenchyme tissue and palate (Figure 1A,B), the inner layer of the
optic cup (the future nervous layer of the retina), in the tissue of the
first brachial arch and in the developing gut (Figure 1B), ). Lrrk2
was expressed at higher level besides the head mesenchyme mainly
in the urogenital ridge (Figure 1C,D). At stage E12.5, further Lrrk1
expressing domains became visible in the epithelia of the nose and
mouth (Figure 1E) and significant Lrrk2 expression was observed in
Rathke’s pouch as part of the developing pituitary gland
(Figure 1F). Again, Lrrk1 and Lrrk2 could not be detected in the
developing central nervous system, however, one hot spot of
expression was the choroid plexus. Furthermore it is noteworthy
that both genes were strongly expressed in the meninges – a non-
neuronal tissue directly surrounding the developing central
nervous system (CNS) (Figure 1E,F). At stage E14.5 (Figure
S1C–E for Lrrk2) and E15.5 (Figure 1G,H), robust Lrrk1 and Lrrk2
expression was detected in parts of the developing kidney, lung,
liver and heart (Figure 1G,H). Interestingly, the expression of Lrrk1
and Lrrk2 at this developmental stage showed a high degree of
overlap, however, the localization within the tissues was diverse in
some cases. For example, Lrrk2 mRNA in the developing kidney
was more or less restricted to structures like the metanephric
vesicles (Figure S1E), which was not the case for Lrrk1 expression
(data not shown). In agreement, both Lrrk1 and Lrrk2 were still
strongly expressed in the choroid plexus (Figure 1G,H and Figure
S1C), while no expression was observed in other parts of the
embryonic brain until birth (data not shown). Taken together, the
expression pattern of Lrrk1 and Lrrk2 were largely overlapping
during embryogenesis in many organs and structures. However,
Lrrk1 expression seemed to be stronger and more widespread than
expression of Lrrk2.
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Comparative Expression Analysis of Lrrk1 and Lrrk2 in the
Murine Postnatal, Adult and Aged Brain
Distinct expression of Lrrk2 in neural cells of the CNS were
observed around birth (Postnatal day 0, P0), where weak Lrrk2
expression was found in the entire brain, specifically in the
developing cortex, cerebellum and brain stem (Figure S2A).
During postnatal development until P7, the overall neuronal ISH
signals but also the expression in distinct domains like cortex,
striatum and olfactory bulb increased notably (Figure S2B).
Between P7 and P21, the level of Lrrk2 expression in the forebrain
and midbrain varied in a highly dynamic manner. As an example,
Lrrk2 ISH signals in the striatum increased in the forebrain and
surpassing the cortical expression level, which remained rather
unchanged (Figure 2A,C,E). Also, the level of Lrrk2 increased
considerably in hippocampus and posterior cortex, while expres-
sion in the substantia nigra (SN) was constantly low
(Figure 2B,D,F). In contrast to Lrrk2 (Figure 3D), Lrrk1 mRNA
was barely detectable in the postnatal brain, namely at P21. At this
time-point of development, only the non-neuronal meninges and
the mitral cell layer of the olfactory bulb showed faint ISH signal
for the Lrrk1 specific probe (Figure 3A and Figure S4I).
In the adult (older than 6 weeks) mouse brain, strong Lrrk2 ISH
signals were present all over the brain, with highest level in the
forebrain, the olfactory tubercle and the striatum (Figure 3E and
Figure S4B). In addition, strong Lrrk2 expression was also observed
in the motor, somatosensory and visual cortex (Figure S3), as well
as in the anterior olfactory nucleus and the hippocampus. Herein,
Figure 1. Comparative expression analysis of Lrrk1 and Lrrk2 mRNA during embryogenesis. ISH for Lrrk1 (left part) and Lrrk2 (right part)
mRNA in sections from E10, E12.5 and E15.5 embryos. For each embryo, a brightfield image (e.g. A, for anatomical orientation) and a darkfield image
(e.g. A’, ISH signals in white) are shown. (A–D) At E10, small hotspots of Lrrk1 expression were observed only in the cephalic mesenchyme (Cm in
A+B), the palate and the optic stalk (Oc in B), while Lrrk2 mRNA was found basically in the urogenital ridge (Ur in C, arrow). Note that at this stage of
gestation expression of Lrrk1 and Lrrk2 was virtually absent from the developing CNS (A–D). (E,F) At E12.5, additional spots for Lrrk1 expression were
visible in the epithelia of the nose and mouth (Nc in E) and for Lrrk2 expression in the choroid plexus (Cp in F, arrow) and developing pituitary gland
(Pi in F). (G,H) Around E15.5, Lrrk1 and Lrrk2 expression became stronger in several organs of the embryos (G+H) including liver (Li), kidney (Ki), lung
(Lu) and heart (Pe) as well as in the choroid plexus (Cp, arrows). Ao, Aorta; Ba, branchial arch; Cm, cephalic mesenchyme; Cx, cortex; Cp, choroid
plexus; Da, dorsal aorta; Dg, dorsal root ganglia; Fb, forebrain; Ge, ganglionic eminence; Gu, gut; Hb, hindbrain; Hl, hind limb; Id, intervertebral disc; In,
incisive; Jl, lower jaw; Ki, kidney; Lb, limb but; Li, liver; Lu, lung; Mb, midbrain; Nc, nasal cavity; Oc, optic cup; Os, optic stalk; Pa, palate; Pe, pericardium;
Rp, Rathke’s pouch; Sp, spinal cord; Ur, urogenital ridge; V4, fourth ventricle; Vl, lateral ventricle. Orientation of sections: A+C, coronal; B, horizontal;
D–H, sagittal. Scale bars represent 500 mm in A–D, 1 mm in E–H.
doi:10.1371/journal.pone.0063778.g001
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specifically the pyramidal cells of the hippocampus proper (CA1,
CA2 and CA3) as well as the dentate gyrus were robustly labeled
(Figure 3E and Figure S4F). Lrrk2 expression was also found in the
subventricular zone (Figure S4D) – the second region of adult
neurogenesis besides hippocampus. Interestingly, the dopaminer-
gic system of the ventral midbrain (built up by the SN pars
compacta and pars reticulata, as well as the ventral tegmental area)
showed only comparable low level of Lrrk2 expression (white
arrows in Figure 2D,F; Figure 3E and Figure S4H). In the
hindbrain, strongest ISH signals were found in the purkinje cell
layer and molecular layer of the cerebellum (Figure 3E and Figure
S4J). In the adult pituitary gland, Lrrk2 can be observed in the
Figure 2. Expression analysis of Lrrk2 mRNA in the forebrain and midbrain of postnatal mice. ISH for Lrrk2 mRNA in coronal sections of
forebrain (left part) and midbrain (right part) from postnatal day 7, postnatal day 21 and adult mice. Note that expression of Lrrk2 is highly dynamic in
the postnatal forebrain. While the expression level in the striatum and the olfactory tubercle seem to increase dramatically during development, the
Lrrk2 level in cortex remain rather unchanged (A,C,E). On the level of the midbrain, ISH signals for Lrrk2 augment considerably in the hippocampus
and cortex, while the level in midbrain structures like the Substantia nigra pars compacta (white arrows, SNc) remain quite low (B,D,F). Abbreviations:
Cc, corpus callosum; Cx, cortex; Cp, choroid plexus (white arrowhead in B’); Cs, superior colliculus; Hi, hippocampus; Ot, olfactory tubercle; Pc, piriform
cortex; Pn, parafascicular nucleus; Rn, red nucleus; Se, septum; SNc, SN pars compacta; SNr, SN pars reticulata; St, striatum. Scale bars represent 1 mm.
doi:10.1371/journal.pone.0063778.g002
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anterior and especially in the intermediate lobe (data not shown)
which constitute the adenohypophysis, but not in the posterior
lobe (neurohypophysis). During ageing, no significant differences –
neither in expression pattern nor in the expression level – were
observed in up to 24 month old mice (data not shown). Lrrk1
retained its postnatal expression pattern also in adulthood (Figure 3
and Figure S3–4).
Taken together, the expression of Lrrk2 in the murine CNS
became detectable around birth and increased during early
postnatal development. In adult mice, the level of Lrrk2 mRNA
in the forebrain and hindbrain were higher than in the midbrain.
The general Lrrk2 expression patterns observed in six week old
brains sustained stable during adulthood. In contrast to Lrrk2,
Lrrk1 was barely detectable in the adult mouse brain and only
present in the mitral layer cell layer in the olfactory bulb where no
prominent Lrrk2 expression can be found.
Quantitative Analysis of Lrrk2 mRNA and Protein Level in
the Adult CNS
Since Lrrk1 was barely detectable in the adult mouse brain, all
further analyses were focused on Lrrk2. To obtain quantitative data
Figure 3. Comparative expression analysis of Lrrk1 and Lrrk2 mRNA in the brain of adult mice. ISH for Lrrk1 (top part) and Lrrk2 (bottom
part) mRNA in sections from P21 (A–D) and adult mice (E). Note that Lrrk1 mRNA is barely detectable in the adult mouse brain and only visible in the
non-neuronal meninges (white arrow) and the olfactory bulb (white arrowhead) (A). A detailed view onto the adult olfactory bulb depicts the solely
neuronal expression of Lrrk1 in the mitral cell layer (B). Specificity of the Lrrk1 signals were verified by using the corresponding sence-probe as
negative control (C). In contrast, strong Lrrk2 expression can be detected in various regions throughout the postnatal (D) and adult CNS (E).
Abbreviations: An, anterior olfactory nucleus; Bs, brain stem; Cb, cerebellum; Cc, corpus callosum; Cm, motor cortex; Co, cortex; Cp, choroid plexus;
Cs, somatosensory cortex; Cv, visual cortex; Gl, glomerular layer; Gr, granual layer; Hi, hippocampus; Me, meninges; Mi, mitral layer; Ob, olfactory bulb;
Ot, olfactory tubercle; Pn, parafascicular nucleus; Pl, plexiform layer; Po, pons; SNc, substantia nigra pars compacta; St, striatum; Th, thalamus; Lv,
lateral ventricle. Scale bars represent 1 mm (A, D, E) and 500 mm (B).
doi:10.1371/journal.pone.0063778.g003
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with regard to LRRK2 expression level in the adult brain, we
performed quantitative PCR (qPCR) and Western blot analyses on
total RNA and protein samples from different brain regions
(Figure 4A). Therefore, mouse brains were separated into their two
hemispheres: one half was used for Western blot and the other for
qPCR analysis. These were separated into nine different brain
regions and utilized to prepare total RNA or protein samples. To
allow a direct comparison between Lrrk2 mRNA and protein level,
the relative expression level for all brain regions have been
summed up and set to 100%. Interestingly, the pattern of protein
expression found by Western blot matched the mRNA level
observed by ISH (compare Figure 3 and Figure 4B). The highest
LRRK2 protein level was found in samples from the posterior
cortex (27.2% (63.7%) of total LRRK2 protein in the adult brain),
followed by striatum, hippocampus and cerebellum (Figure 4B).
Also by qPCR, the highest Lrrk2 mRNA level were found in
samples from cortex and striatum, followed by cerebellum, brain
stem and hippocampus (Figure 4B). Apart from striatum, there
were no remarkable discrepancies between the relative protein and
mRNA level in the different brain regions. However, the striatal
mRNA level was 32.9% (66.2%) of the total Lrrk2 mRNA, while
the very same region contained only 17.6% (64.0%) of the total
LRRK2 protein. A possible explanation for this phenomenon
could be posttranscriptional regulation of LRRK2 in the striatum
via specific microRNAs and/or transport of the protein. However,
further analyses would be necessary to proof this hypothesis.
Taken together, qPCR and quantitative Western blot analyses
further verified the ISH-based expression pattern of Lrrk2.
Analysis of Lrrk2-expressing Neuronal Subtypes
ISH, Western blot and real-time PCR analyses revealed highest
Lrrk2 expression level in samples from cortex and striatum,
wherein the last one is known to be the major target area of the
dopaminergic neurons from the SN. Based on this observation we
studied in detail the cellular expression of Lrrk2 in the striatum by
double in situ-hybridization/Immunohistochemical (ISH/IHC)
stainings: on paraffin sections of the adult striatum nonradioactive
ISH (nonfluorescent dark precipitate as signal indicating strong
Lrrk2 expression) were performed, followed by fluorescent IHC for
different neuronal markers. High magnifications of radioactive
ISH brightfield pictures gave further insights into the cellular
expression of Lrrk2. High expression was associated with neurons
as identified by their typical morphology in the cresyl violet (CV)
counterstaining (black arrows in Figure 5A). Most but not all non-
neuronal cells, marked by their more condensed appearance in
CV stainings, were devoid of Lrrk2 mRNA (white arrowheads in
Figure 5A) We could confirm this finding by a high overlap of
Lrrk2 mRNA expressing cells with the neuronal marker NeuN
(neuronal nuclei antigen) in striatal sections by ISH/IHC stainings
(data not shown), indicating a predominant but not exclusive
neuronal expression of Lrrk2. In addition, virtually all striatal cells
strongly expressing Lrrk2 mRNA were also positive for the
dopamine and cAMP regulated phosphoprotein 32 (DARPP-32)
(data not shown); a marker for medium spiny neurons (MSNs) in
the striatum [40], suggesting that Lrrk2 plays a functional role in
dopaminoceptive neurons. Hence, we studied the cellular expres-
sion of Lrrk2 mRNA in the two canonical dopaminergic circuits of
the basal ganglia, the direct and indirect pathway, which are
marked by the expression of either dopamine receptors D1
(DRD1a) or D2 (DRD2), respectively. The quantification of ISH/
IHC for Lrrk2 and DRD1a depicted in the striatum 36% of the
cells being Lrrk2-positive, 25% DRD1a-positive and 39% double
positive (Figure 5B,D). In case of the DRD2 ISH/IHC, 38% of the
cells were solely Lrrk2-positive, 24% DRD2-positive and 37%
double positive cells could be detected (Figure 5C,E). This data
indicates that neither the direct nor the indirect pathway
preferentially expresses Lrrk2. In addition it could be observed
that only subpopulations show strong Lrrk2 expression in both
pathways.
Analysis of Lrrk2 mRNA Transcripts and Splice Variants
Alternative splicing increases the diversity of mRNAs expressed
from the genome, which has profound functional effects [41].
Therefore, we completed the detailed Lrrk1 and Lrrk2 expression
analysis by determining Lrrk2 splice variants and their expression
in various brain regions and organs from adult mice. Therefore,
we first studied the genomic organization of Lrrk2 for the presence
of exons which could be spliced out without causing dramatic
rearrangements of the residual Lrrk2-transcript (i.e. exons with a
number of base-pairs that is divisible by three and thus can be
skipped without causing a frame-shift in the residual mRNA
coding sequence). Thereafter, we performed six different RT-PCR
analyses using primer pairs amplifying the regions of exons 4–9,
16–21, 30–34, 35–39, 41–45 and 47–51 (Figure S5A). All
reactions produced single amplicons representing the canonical
Lrrk2 mRNA (Figure S5B–F) except the primer combination for
exons 4 to 9, which revealed an additional, smaller band of
unknown origin (Figure 6B). We analysed RNA samples from the
brain regions with the highest Lrrk2 expression (striatum and
cortex), but also cerebellum, olfactory bulb and hippocampus. In
addition, samples from several organs were analysed using the
same primers. Interestingly, all samples analysed showed this
additional lower band in a comparable ratio. Sequence analysis of
the fragments revealed a novel splice variant in which exon 5
(135bp) is absent (Figure S6). To test for cell-type-specific
expression within the CNS, the same primers were used to
analyse RNA samples from primary neuronal, microglia and
astrocyte cultures, which all were prepared from cortical tissues of
C57Bl/6J mice. As already suggested by the ISH expression
analysis, the endogenous Lrrk2 transcript could be detected in all
three cell types with several primer pairs (data not shown). Using
primers for exons 4–9, we found the same pattern in samples from
neurons and microglia as observed in organs and brain tissues
(Figure 6C). However, in astrocytes the splice variant without exon
5 was dominantly expressed whereas the full length transcript was
barely detectable (Figure 6C). In addition, we performed a qPCR
expression analysis using a probe located within exon 5 specific for
the full-length Lrrk2 transcript and a probe located in the junction
between exon 4 and 6 specific for the alternative Lrrk2 mRNA
transcript with skipped exon 5 (Figure 6F). Putative differences in
the sensitivity of the primer combinations and probes may not
allow a direct quantitative comparison between endogenous and
alternative form. Nevertheless, the results confirmed a pronounced
expression of alternative Lrrk2 mRNA transcript in primary
astrocytes compared to primary neurons and microglia.
Next, we analysed all samples for the presence of an alternative
exon 42a (containing several stop codons), which was already
annotated in ensembl.org as part of an alternative processed
transcript (ensembl.org sequence ENSMUST00000140734, Fig-
ure S7). In contrast to the full length Lrrk2 transcript, which
consists of 51 exons, 8275 base-pairs and 2527 amino acids
(ensembl.org sequence ENSMUST00000060642), the annotated
sequence encompasses only 19 of these exons (3452 base-pairs),
starts in exon 24 and ends with the alternative exon 42a (Figure
S5). There is no information available about the sequence which is
59 of the annotated 19 exons. Thus, it could be possible, that this
annotation is part of an alternative Lrrk2 transcript, that starts
regularly with exon 1, but ends with exon 42 (6456bp and 2152
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amino acids long). To confirm the expression of this transcript, we
performed RT-PCR analyses using primers amplifying the
sequence between exon 39 and the alternative exon 42a
(Figure 6D). Interestingly, expression of this alternative exon 42a
could be identified in all brain regions and organs analysed.
Sequencing of the fragment confirmed the alternative splicing
event from the canonical exon 41 to the alternative exon 42a
(Figure S8). NCBI blast of the corresponding sequence demon-
strated that the alternative exon 42a was located between exons 41
and 42 within the published Lrrk2 sequence (Figure S8). To answer
the question whether the expression is – like in case of skipped
exon 5 – limited to certain cellular subtypes in the murine CNS,
we analysed RNA samples from primary neuronal, microglia and
astrocyte cultures and found identical patterns in samples from
neurons and astrocytes (Figure 6E). Interestingly, no band was
detectable in samples from microglia, indicating that these cells
may not process transcripts containing the alternative exon 42a.
For confirmation, we utilized a qPCR analysis using specific
primers and probes for the full-length Lrrk2 transcript (i.e. primers
located in the endogenous exon 42) and primers and probes
located in the alternative exon 42 (Figure 6G). As expected, in
primary microglia we could barely detect the expression of the
shortened Lrrk2 mRNA transcript ending in the alternative exon
42, whereas primary neurons and astrocytes show significant
higher expression of this variant.
Taken together, we were able to identify and describe a novel –
and so far unknown – splice variant of Lrrk2 (skipped exon 5) and
confirm the presence of an already published alternative transcript
(alternative exon 42a) in RNA samples from different brain
regions, organs and primary neuronal cell cultures. In addition, we
Figure 4. Expression analysis of Lrrk2 mRNA and protein in various brain regions from adult mice. Quantifications of Lrrk2 level in
various brain regions by qPCR (mRNA) and Western blot (protein). Before calculation, LRRK2 protein level from Western blot analyses (A,
representative Western blot) were normalized to beta-actin (ACTB) as loading control and Lrrk2 mRNA level from qPCR to a beta-actin control
accordingly. (B) To allow a direct comparison between Lrrk2 mRNA and protein level, the sum of all individual relative expression level were set to
100% in both cases ({percentage brain region}z. = {relative level brain region}/{sum of all relative level}6100%). The definition of brain regions used
for this analysis is indicated in the figure legend (B). Abbreviations: Ac, anterior cortex; Bs, brain stem; Cb, cerebellum; Dc, diencephalon; Hi,
hippocampus; Mb, midbrain; Ob, olfactory bulb; Pc, posterior cortex; St, striatum.
doi:10.1371/journal.pone.0063778.g004
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found differential expression of these new transcripts in a cell-type
specific manner.
Discussion
Several studies analyzing mRNA and protein expression of
LRRK1 and LRRK2 in mouse, rat, pig and human samples of
brain, organs/tissues and cells have been published so far,
demonstrating largely ubiquitous expression of Lrrk2 in the CNS
and peripheral tissues [30,31,40–54]. Our present study presents
novel findings, which gives potentially new insights into the
physiological function of these proteins. To our knowledge, this is
the first time that Lrrk1 and Lrrk2 expression was comparatively
analysed, qualitatively and quantitatively, using several indepen-
dent and highly sensitive analytical methods. With this we have
thus described all important aspects like anatomical localization,
expression level, distribution in neuronal cell populations and
presence of splice variants in a single study.
We show a detailed analysis of Lrrk1 and Lrrk2 expression during
embryonic development (E7.5 to E15.5) as well as in the postnatal
(P0 to P21) and adult (.6 weeks) brain of C57BL/6J mice. For this
purpose, we used radioactive labeled riboprobes, which are more
sensitive than non-radioactive probes and thus are able to identify
low expression sites [37]. In addition, we used up to 6 different
overlapping and not overlapping riboprobes per gene (Figure S9),
which all showed identical results after hybridization (data not
shown). We also used the corresponding sense RNA probes as
negative controls to ensure the specificity of the expression pattern.
We found moderate ISH signals for Lrrk1 and Lrrk2 during
embryogenesis (E10 to E12.5) with their expression patterns
showing common characteristics in many organs and structures.
Total level of Lrrk1 were slightly stronger and more widespread
than Lrrk2. With ongoing organogenesis (E15.5), the overall
mRNA level of both genes increased and their non-neuronal
expression domains became broader. Increasing Lrrk2 expression
during embryonic development was also described by Zechel et al.,
who performed ISH with DIG-labeled riboprobes on brain
sections from C57BL/6 mice and did not observe Lrrk2 expres-
sion in the CNS before embryonic stage E12.5 [54]. In addition,
similar differences in total brain mRNA level of Lrrk1 and Lrrk2
were shown in two independent studies using radioactive ISH and
qPCR [30,31]. First, in rat embryos, Westerlund et al. determined
postnatal day P8 to be the earliest time-point in which Lrrk2
expression could be observed in the CNS, while widespread Lrrk1
expression was found already at embryonic stage E 13.5 [31].
Secondly, Biskup et al. showed, in samples from whole mouse
brains, that between embryonic stages E11.5 and E17.5 the
relative mRNA level of Lrrk1 were constantly higher than those of
Lrrk2 [30]. The fact that we and others – in contrast to our ISH
studies - detected considerable level of Lrrk1 and Lrrk2 mRNA by
RT-PCR or real-time PCR [30,54] in samples of whole embryos
and embryonic brain tissues, even at early stages of embryonic
development, is not surprising. This can be explained by the
observed strong expression of both genes in the choroid plexus and
the meninges, which tightly surround the complete CNS and its
ventricular system. In line with the non-neuronal expression of
Lrrk2 during development is the expression in the Rathke’s pouch;
the non-neural origin of the adenohypophysis. Strikingly, in
adulthood Lrrk2 expression can be found in the anterior and
intermediate lobe (adenohypophysis) and not in the posterior lobe
(neurohypophysis) (data not shown), which is composed of cells of
the ventral diencephalon [55]. Interestingly, there are also two
groups presenting stronger ISH signals for Lrrk1 in the developing
CNS of rats [31] and for Lrrk2 in the developing CNS of mice [54].
Nevertheless, even though these data may conflict with our
findings, they could possibly originate from species or technical
differences between their and our studies.
During embryonic development, we observed much stronger
ISH signals for Lrrk1 and Lrrk2 expression in kidney, lung, liver
and heart when compared to all CNS regions. This is fully in line
with other comparative expression studies, most of which
Figure 5. Cellular expression analysis of Lrrk2 mRNA in the striatum of adult mice. (A) High magnification of a representative brightfield
ISH image using radioactive-labeled Lrrk2-specific riboprobes and counterstained by cresyl violet: Lrrk2 mRNA is predominantly expressed in neurons
(black arrows, Lrrk2-positive neurons; white arrows, Lrrk2-negative neurons; black arrowheads, Lrrk2-positive glia; white arrowheads, Lrrk2-negative
glia). (B, C) Representative images of double in situ2/Immunohistochemistry (ISH/IHC) in the medial part of the putamen: ISH for Lrrk2 using DIG-
labeled riboprobes (non-fluorescent black precipitate) followed by IHC stainings (green) for the two main dopamine receptors D1 (DRD1a) and D2
(DRD2). (D, E) Quantification of the Lrrk2/DRD1a and Lrrk2/DRD2 ISH/IHC stainings in the striatum revealed 36% Lrrk2-positive, 25% DRD1a-positive
and 39% double positive cells. In case of the DRD2 in situ2/Immunohistochemistry, 38% Lrrk2-positive, 24% DRD2-positive and 37% double positive
cells could be detected. Scale bar represents 25 mm.
doi:10.1371/journal.pone.0063778.g005
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Figure 6. Qualitative expression analysis of alternative Lrrk2mRNA transcripts. RNA samples from different brain regions and organs were
analysed by RT-PCR using a primer combination that amplifies Lrrk2 transcripts between exon 4 and exon 9 (A). Note that there is – beside the band
of the endogenous Lrrk2 (ex.4–9) – an additional lower band visible in all samples analysed representing a mRNA where exon 5 is spliced out (ex.5
skipped) (B). The same primers were used to analyse RNA samples from primary neuronal cultures (i.e. neurons, microglia and astrocytes) (C).
Interestingly, the band representing the splice variant without exon 5 (E5 skipped) was dominantly expressed in samples from astrocytes, while the
band for the endogenous transcript (E4–E9) was almost completely missing in these cells. (D) RNA samples were analysed by RT-PCR using primers
that amplify Lrrk2 transcripts between exon 39 (E39) and an alternative exon 42a (ex.42a). Note that the alternative exon 42a is present in all samples
analysed (ex.39–42a). (E) The same primers were used to analyse RNA samples from primary neuronal cultures (i.e. neurons, microglia and astrocytes).
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quantified mRNA level of different organs and brain regions by
qPCR: (i) Zimprich et al. presented highest Lrrk2 mRNA level in
human lung [8]. (ii) Biskup et al. described that both Lrrk1 and
Lrrk2 mRNA level were much stronger in murine neonatal lung,
heart and kidney than in whole brain samples [30]. (iii) Larsen
et al. demonstrated highest Lrrk2 mRNA expression in porcine
testis, spleen and lung [45]. (iv) Maekawa et al. showed highest
Lrrk2 mRNA level in kidney, spleen, lung and testis even in
samples from adult (20, 50 and 98 week old) mice [46]. Taken
together, Lrrk1 and Lrrk2 are widely expressed during whole
embryogenesis in non-neuronal tissue whereas their expression in
neural tissue is barely detectable. On the other hand, Lrrk2 mutant
mice (knockout, LRRK2 overexpression or introduction of point-
mutations) do not show gross developmental phenotypes; they
survive and show normal growth and life span [56–59]. This
suggests that Lrrk2 function during development is not necessary
for survival, but is required for non-vital physiological function
within non-neuronal tissues.
After birth, Lrrk2 expression became robustly detectable in the
murine CNS. It then increased further during early postnatal
development in a highly dynamic manner and reached its
maximum level around 6 weeks after birth, remaining stable
throughout the lifespan. Thus, we confirmed the observations
from other studies, namely ascending expression level of Lrrk2
during different stages of postnatal development [31], [25,30]. In
the adult mouse brain, strong ubiquitous Lrrk2 ISH signals were
present, with highest level in striatum, cortex, hippocampus,
cerebellum, anterior olfactory nucleus and brain stem. Interest-
ingly, during these first postnatal weeks synaptogenesis reaches a
peak, specifically in the striatum and cortex [60,61]. This raises the
questions whether Lrrk2 is directly involved in synaptogenesis or is
part of the synaptic machinery. Indeed, a synaptic function of
Lrrk2 – as suggested by its appearance in postnatal stages – is also
supported by the fact that Lrrk2 has been implicated in
neurotransmitter release [36,62]. In addition, LRRK2 protein
expression becomes robustly detectable in primary hippocampal
and cortical neuron-cultures (prepared from E15–16 embryonic
brains) from day 7 onwards: a time point when the neuronal
networks in the cultures are established [36]. Surprisingly, the
mesencephalic region of the substantia nigra (SN), which contains
the most vulnerable neuronal populations affected in PD,
exhibited only moderate Lrrk2 expression in the adult brain: the
target area of these dopaminergic neurons (i.e. caudate putamen in
the striatum) shows the highest level of Lrrk2 mRNA. Most likely
due to the rather low expression level of Lrrk2 in the SNc, there
have been conflicting statements concerning Lrrk2 expression in
this region. Some groups present only low to undetectable level of
Lrrk2 in the SNc of mice [47,53] and rats [41,53]. On the other
hand, others found clearly detectable Lrrk2 expression in the SNc
of humans [40,43,51], mice [44,49,52] and rats [40,42]. Still, the
combination of these and the present study clearly indicates that
Lrrk2 is indeed expressed in the adult SNc.
In contrast to Lrrk2, Lrrk1 was barely detectable in the adult
mouse brain and only present in the mitral cell layer of the
olfactory bulb. It is quite surprising that, despite their high degree
of homology and their comparable expression patterns during
development, the adult brain almost exclusively expresses Lrrk2.
Nevetheless, this finding suggests that LRRK1 does not compen-
sate for LRRK2 function in the adult brain and – as a
consequence – is not responsible for the absence of neurodegen-
eration in genetic animal models of Lrrk2 [62]. Furthermore it may
also explain why, up to now, no PD-associated mutation has been
identified in LRRK1 [28].
We further verified our observed ISH-based expression pattern
of Lrrk2 by exact quantification of mRNA and protein level in
samples from different brain regions using real-time PCR and
Western blot, respectively. The observed patterns match remark-
ably, not only with the strongest Lrrk2 expression domains
identified by our ISH analyses, but also with Northern blot [7],
real-time PCR [48,53,63] and Western blot data [49] published by
other groups. Interestingly, apart from striatum, no discrepancies
between the relative protein and mRNA level in the different brain
regions could be detected, suggesting no major posttranscriptional
regulation of Lrrk2 outside of the striatum. The discrepancy within
the striatum could have manifold explanations including (i)
posttranscriptional regulation of Lrrk2 in the striatum via specific
microRNAs, leading to blocking of translation [64], (ii) reduced
half-life of LRRK2 protein in the striatum due to protein
truncations, protein degradation or diminished protein stabiliza-
tion, (iii) the opposite scenario – increased half-life of the LRRK2
protein in the striatum, so that less mRNA transcripts would be
required to maintain the necessary protein level, or (iv) transport of
the protein from the striatum to other brain compartments. Thus,
further analyses are necessary to distinguish between these
theories.
In the next part of the study, Lrrk2 expression was analysed on
the cellular level in sections from striatum and cortex with focus on
dopaminoceptive neurons. Elucidation of neuronal versus non-
neuronal (i.e. the role of Lrrk2 in microglia function as mediator of
neuroinflammation) localization of LRRK2 could help to under-
stand its physiological function and/or its role in the pathogenesis
of Lrrk2-associated PD [65–67]. Indeed, our studies also confirmed
expression of Lrrk2 in glial cells; however, the bulk of the
expression in the CNS was neuronal. In addition, almost 100% of
the Lrrk2+ cells in the striatum were positive for the MSN-marker
DARPP-32, indicating that Lrrk2 might play a role in dopami-
noceptive neurons. Quantification of double ISH/IHC in the
striatum revealed that about 61% (36% Lrrk2+, 25% DRD1a+,
39% Lrrk2+ and DRD1a+) of DRD1a+ MSNs, representing the
direct pathway, highly express Lrrk2 mRNA. In this regard, MSNs
of the indirect pathway (DRD2+) exhibited almost identical
percentages (38% Lrrk2+, 24% DRD2+, 37% Lrrk2+ and
DRD2+), indicating that only subpopulations of both pathways
express high level of LRRK2. This notion was supported by a
partial colocalization of Lrrk2 with DRD1a+ and DRD2+ neurons
in the striatum. These data confirm the study of Mandemakers
et al. where, via double IHC, LRRK2 protein was shown to
colocalize with DRD1a in striatal cells [47] on the mRNA level.
Our quantitative data also reveal that only subpopulations of both
the direct and the indirect pathway express very high level of
LRRK2. Thus, we hypothesize that Lrrk2 could play a role in both
dopaminergic pathways, which are directly related to the
Interestingly, the alternative exon 42a could not be amplified from primary microglia cDNA. (F) Relative expression level as measured by quantitative
RT-PCR with primers and probes specific for either the endogenous Lrrk2 transcript (full-length Lrrk2), or for the alternative Lrrk2 mRNA transcripts
with skipped exon 5 (ex.5 skipped). The relative expression is depicted as a ratio between endogenous Lrrk2 transcript and the alternative product on
a logarithmic scale. (G) Accordingly for the alternative Lrrk2 mRNA transcript ending in the alternative exon 42a (alt.ex.42), the relative expression
level have been determined by quantitative RT-PCR with specific primers and probes for the alternative product and normalized to the expression of
the endogenous Lrrk2 transcript (full-length Lrrk2).
doi:10.1371/journal.pone.0063778.g006
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neuropathology of PD [68]. Nevertheless, differential function(s) of
Lrrk2 in DRD1a positive and in DRD2 positive subpopulations of
neurons has to be evaluated.
Next, we concentrated on the search for splice variants of the
murine Lrrk2 mRNA transcript in various brain regions and
organs from adult mice. Zimprich et al. [8] (2004) presented the
very first hints for alternative Lrrk2 splicing, when they noticed
weak bands at lower sizes in Northern blot analyses of human
brain samples; this was also observed by an independent group [7].
When they used RT-PCR to quantify transcripts containing exons
1–3, 12–13 and 32–34 however, they did not find significant
differences in the expression level [8]. Later, West et al. described
the presence of at least six transcription start sites upstream of the
first Kozak sequence and one downstream of the first predicted
exon (within intron 1). This would exclude the complete Lrrk2
ORF and produce a protein of unknown biological significance
[69]. However, they also found no evidence for alternate Lrrk2
exons or protein coding sequences [69]. Therefore, we analysed
the comparably large Lrrk2 transcript for exons, which could be
spliced out without causing dramatic rearrangements, and
performed RT-PCR analyses using primer pairs amplifying the
regions of exons 4–9, 16–21, 30–34, 35–39, 41–45 and 47–51.
After screening these six different regions, we were able to identify
a novel – and so far unknown – splice variant of Lrrk2, sparing
exon 5 (135bp).
Ignacio Marin has published, in 2008, the detailed structure of
selected LRRK proteins, including human LRRK2, and described
the presence of 14 N-terminal LRRK2-specific repeats in the
human and mouse sequence [21]. We calculated that exon 5
covers virtually the complete sequence of the fourth repeat. The
lack of exon 5 (and consequently the loss of the fourth repeat) may
result in a protein with altered size (45 amino acids smaller) and
unknown biological significance. Nevertheless, a possible conse-
quence could be a change in the affinity to different LRRK2
binding partners (i.e. alterations in the LRRK2 interactome).
Interestingly, this alternative transcript was present in all samples
analysed. When we analyzed RNA samples from primary
neuronal, microglia and astrocyte cultures (all prepared from
cortical tissues) however, we found identical patterns in neurons
and microglia. Surprisingly, there was a dominant expression of
the splice variant without exon 5 in astrocytes. Thus, astrocytes
may exhibit a different interactome of LRRK2 and therefore
LRRK2 function may differ in neurons and astrocytes. Further-
more, we were able to confirm the presence of an alternative
transcript that contains an alternative exon 42a (including several
stop codons) and was located between the endogenous exons 41
and 42 (annotated in ensembl.org). Interestingly, we also found
cell-type specific expression patterns of these transcripts between
the different primary cell cultures. While neurons and astrocytes
both process the transcript containing the alternative exon 42a, no
band was visible in microglia. This suggests a rather low
expression of the alternative variant compared to the full-length
Lrrk2 transcript. As mentioned above, we have no information
about the sequence that is 59 of exon 39 in this transcript.
Assuming that the transcript starts regularly with exon 1, it could
induce a maximum protein product of 239 kDa (in contrast to the
280 kDa full-length LRRK2 protein). This could somehow
explain why we (data not shown) and others
[30,46,47,50,65,70,71] observe additional bands in Western blot
analyses, which could fit to the calculated size of a truncated
LRRK2 isoform. Considering the complex architecture of the
LRRK2 protein, implying that Lrrk2 is involved in more than one
cellular process [72], we found that the endogenous exons 41, 42
and 43 cover the complete end of the MAPKKK domain [73].
Splicing that introduces an alternative exon 42a will lead to an
early truncation of the protein (due to its included stop codons,
and may seriously influence its enzymatic activity (due to lack of
the c-terminal part of the kinase domain). In addition, the
complete WD40 domain would also be absent in such a
truncation. Jorgensen et al. demonstrated that removing the
WD40 domain prevents complex formation and autophosphor-
ylation but also blocks the neurotoxicity of LRRK2 PD mutations
[74]. Moreover, it was shown that fragments of LRRK2
containing the ROCO domain mediate LRRK2 kinase inhibition
[75]. It is thus tempting to speculate that the splice variant with
alternative exon 42a is acting as an inhibitor of intrinsic LRRK2
function. The absence of this variant in microglia would, in turn,
render this cell type more susceptible to LRRK2 pathogenic
mutations via further stimulation or through missing the regulation
of its potentially toxic kinase activity. It is interesting to note that
attenuated inflammatory responses after knockdown of LRRK2 in
microglia indicate that it may be a positive regulator of
neuroinflammation [67]. Taken together, we observed cell-type
specific differences in the expression of full-length, exon 5-skipped
and truncated (E1–E42a) transcripts. Thus, we assume that Lrrk2
features different physiological functions in different neural cell
populations and cell-type specific differences in its enzymatic
functions and its interactome. This is in full agreement with Lewis
et al. [72], who postulated that alterations in different glial cell lines
could selectively affect susceptible neuronal populations in PD.
Furthermore, Lrrk2 may be regulated by different signals;
interacting with different upstream regulators or downstream
effectors: phosphorylating different substrates, and so form –
depending on the presence of appropriate cofactors, interacting
proteins or other favorable environmental conditions – tissue-
selective or non-selective signaling complexes. This results in cell-
type specific molecular effects and pathology [72]. Further efforts
are necessary to figure out if these splicing patterns are conserved
between mouse and humans, or if they represent interesting
differences between species.
In conclusion, we present here a substantial and detailed
analysis of Lrrk1 and Lrrk2 expression, focusing on qualitative and
quantitative aspects (anatomical localization, expression level,
distribution in neuronal cell populations and presence of splice
variants) and covering numerous stages ranging from ES cells,
embryonic development until the postnatal and adult brain. To
our knowledge, we show for the first time a quantitative analysis of
colocalization between Lrrk2 mRNA and both DRD1a and DRD2
expression in MSNs of the striatum. In addition, we were able to
identify a novel splice variant of Lrrk2 (skipped exon 5) and confirm
an annotated transcript (alternative exon 42a) in RNA samples
from different brain regions, organs and primary neuronal cell
cultures. Besides that, we found cell-type specific alterations in the
transcript expression patterns in the different neuronal lineages.
Supporting Information
Figure S1 Expression analysis of Lrrk2 mRNA in early-
to midgestation embryos by RT-PCR and in situ
hybridization (ISH). (A) RNA samples from ES cells and
early embryos (E8.5 to E12.5), as well as newborn mice (P0) and
adult kidney, which served as positive controls, were analysed by
RT-PCR for Lrrk2 expression. NoRT, negative control. (B) ISH
for Lrrk2 mRNA in sections from E7.5 embryos. Depicted is a
brightfield image (B) for anatomical orientation and a darkfield
image (B’) showing the ISH signals in white). Note the strong
mRNA signal in the parietal yolk sac (arrowhead) and the decidua
(arrow). (C–E) ISH for Lrrk2 mRNA in sections from E14.5
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embryos. The overview sagittal section exhibits strong expression
in the choroid plexus (Cp), in chondral structures of the nasal
capsule and the kidney (Ki) (C). Detailed view of the lower jar
reveales strong Lrrk2 expression in the primordium of upper and
lower incisive tooth (D). Detailed view of the developing kidney
with strong expression in the metanephric vesicles (arrows) (E).
Abbreviations: Al, allantois; Ch, chorion; Cp, choroid plexus; Cx,
cortex; Dc, decidua; Df, forelimb digit; Ee, embryonic ectoderm;
Em, embryonic mesoderm; En, embryonic endoderm; Ex,
exocoelomic cavity; Id, intervertebral disc; In, incisive; Ki, kidney;
Li, liver; Lj, lower jar; Lu, lung; Py, parietal yolk sac; To, tongue.
Scale bars represent 200 mm in B, 2 mm in C, 250 mm in D–E.
(TIF)
Figure S2 Expression analysis of Lrrk2 mRNA in the
postnatal mouse brain. ISH for Lrrk2 mRNA in sections from
P0 and P7 mice. For each brain, a brightfield image (left image, for
anatomical orientation) and a darkfield image (right image, ISH
signals in white) are shown. (A) Weak Lrrk2 expression is detected
in the murine CNS for the first time directly after birth (in P0
sections), with signals present in the developing cortex (Cx),
cerebellum (Cb) and brainstem (Bs). Strong Lrrk2 mRNA
expression can be detected in the choroid plexus (white arrows
in A9). (B) At stage P7, Lrrk2 mRNA level in forebrain structures
like cortex, striatum (St) and olfactory bulb (Ob) further increases.
Note that the strong signals in the choroid plexus (white arrows in
B9) persist throughout development. Abbreviations: Bs, brain stem;
Cb, cerebellum; Cp, choroid plexus; Cx, cortex; Hi, hippocampus;
Ht, hypothalamus; Mb, midbrain; Ob, olfactory bulb; St, striatum;
Ta, Thalamus. Scale bars represent 2 mm.
(TIF)
Figure S3 Expression analysis of Lrrk1 and Lrrk2
mRNA in the adult visual cortex. ISH for Lrrk1 (A) and
Lrrk2 (B) mRNA in sagital sections from adult mice. As a negative
control (C), a sense probe has been used. Note the strong
expression of Lrrk2 mRNA in the cortical layers 2 to 5a, whereas
ISH for Lrrk1 mRNA only depicts background staining compa-
rable to the negative control. Abbreviations: I to VIb indicate the
different cortical layers. Scale bars represent 200 mm.
(TIF)
Figure S4 Microautoradigraphy of Lrrk1 and Lrrk2
mRNA in different regions of the adult mouse brain.
High magnification brightfield images depicting positive ISH
signal for Lrrk1 or Lrrk2 mRNA as condensed black granules: (A–
B) Highest level of Lrrk2 expression in the murine CNS is detected
in the striatum. No Lrrk1 signal can be detected. (C–D) The
subventricular zone (SVZ) is showing Lrrk2 but not Lrrk1
expression both in ependymal cell as well as in deeper layers of
the SVZ (arrows in D). Note also the strong Lrrk2 expression in
the choroid plexus. (E–F) The pyramidal cells hippocampus
proper show the highest level Lrrk2 mRNA expression in this
region. Nevertheless also other regions show positive signal. ISH
for Lrrk1 only depicts background signal. (G–H) In the substantia
nigra Lrrk2 expression can be found predominantly in the pars
compacta (arrows in H). Again Lrrk1 mRNA could not be
detected. (I–J) In cerebellum, strongest Lrrk2 expression can be
found in the purkinje cells (arrows in J). Significant Lrrk1
expression is limited to the meninges (arrows in I). Abbreviations:
CA3, CA3 region of the hippocampus proper; Cp, choroid plexus;
DG, dentate gyrus; Ec, ependymal cells; GL, granular layer of the
cerebellum; Hi, hippocampus; Ht, hypothalamus; LV, lateral
ventricle; Me, meninges; ML, molecular layer of the cerebellum;
PC, purkinje cell layer; SNpc, substantia nigra pars compacta;
SNpr, substantia nigra pars reticulata; SVZ, subventricular zone;
Ta, Thalamus. Scale bars represent 50 mm.
(TIF)
Figure S5 Qualitative expression analysis of Lrrk2
mRNA transcripts. (A) Schematic overview of the Lrrk2
genomic sequence and location of the 51 exons, which code for
the full-length Lrrk2 mRNA. Exons with a length (number of base-
pairs) that is divisible by three are highlighted in green (i.e. these
exons could theoretically be skipped without resulting in a frame-
shift of the residual mRNA coding sequence). Areas of the Lrrk2
gene which have been analysed by RT-PCR are indicated above.
Sequence is based on the NCBI accession number
NW_001030577.1. (B–F) RNA samples from different brain
regions and organs were analysed by RT-PCR using primers that
amplify Lrrk2 transcripts between exons 16 and 21 (B), exons 30
and 34 (C), exons 35 and 39 (D), exons 41 and 45 (E), and exons
47 and 51 (F). Note that there are no additional bands visible in all
samples analysed.
(TIF)
Figure S6 Sequence analysis of the novel Lrrk2 splice
variant lacking exon 5. (A) Sequencing chromatogram of the
boundary region between exons 4 and 6 indicating the skipping of
exon 5. (B) The sequence of the endogenous Lrrk2 (top row) was
aligned to the sequence of the alternative processed transcript with
skipped exon 5 (bottom row). The resulting protein sequence and
positions of the LRRK2-specific repeats (underlined amino acids)
are indicated below. (C) Schematic overview of the endogenous
LRRK2 protein structure (top) versus the putative protein product
lacking exon 5 (deleted LRRK2-specific repeat indicated in red).
(TIF)
Figure S7 Schematic overview of the endogenous Lrrk2
and an alternative processed transcript. (A) The full length
Lrrk2 transcript consisting of 51 exons, 8275 base-pairs and 2527
amino acids (according to ensembl.org sequence EN-
SMUST00000060642) is shown on top. (B) An alternative
processed transcript annotates 19 of these exons and 3452 base-
pairs (according to ensembl.org sequence EN-
SMUST00000140734, shown on bottom). Note that the alterna-
tive processed transcript contains an alternative exon 42a, which is
not present in the endogenous Lrrk2 transcript.
(TIF)
Figure S8 Sequence analysis of the Lrrk2 splice con-
taining an additional exon 42. (A) Sequencing chromatogram
of the boundary region between endogenous exon 41 and
alternative exon 42 (indicating the alternative splicing event). (B)
The sequence of the endogenous Lrrk2 (top row) was aligned to the
sequence of the alternative processed transcript that contains an
alternative exon 42a (bottom row). The resulting protein sequence
is indicated below. (D) Schematic overview of the endogenous
LRRK2 protein structure (top) versus the putative protein product
which is truncated after exon 42a (bottom). Note that the putative
protein is truncated within the MAPKKK domain and there is no
information about the N-terminal part (shaded).
(TIF)
Figure S9 Sequence of primers and probes used in this
study. Probes for qPCR were all 59-labeled with 6-carboxyfluor-
escin (FAM) and 39-labeled with Black Hole Quencher (BHQ-1).
LNA-bases are indicated by bold letters.
(TIF)
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